Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide
as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's
Lymphoma (NHL).